Wolverine Trading’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $5.26M | Buy |
279,600
+118,400
| +73% | +$2.11M | ﹤0.01% | 1355 |
|
|
2025
Q2 | $2.76M | Buy |
161,200
+117,100
| +266% | +$5M | ﹤0.01% | 1446 |
|
|
2025
Q1 | $3.11M | Sell |
44,100
-1,200
| -3% | -$126K | ﹤0.01% | 1299 |
|
|
2024
Q4 | $5.49M | Sell |
45,300
-300
| -0.7% | -$36.8K | 0.01% | 1136 |
|
|
2024
Q3 | $5.68M | Sell |
45,600
-7,300
| -14% | -$1.01M | 0.01% | 961 |
|
|
2024
Q2 | $8.36M | Sell |
52,900
-3,000
| -5% | -$385K | 0.01% | 718 |
|
|
2024
Q1 | $7.24M | Sell |
55,900
-25,800
| -32% | -$3.16M | 0.01% | 797 |
|
|
2023
Q4 | $7.88M | Buy |
81,700
+47,700
| +140% | +$4.58M | 0.01% | 832 |
|
|
2023
Q3 | $4.12M | Buy |
34,000
+5,700
| +20% | +$644K | ﹤0.01% | 1113 |
|
|
2023
Q2 | $3.18M | Sell |
28,300
-3,900
| -12% | -$503K | ﹤0.01% | 1199 |
|
|
2023
Q1 | $4.38M | Sell |
32,200
-15,500
| -32% | -$2.01M | 0.01% | 911 |
|
|
2022
Q4 | $6.18M | Buy |
47,700
+20,500
| +75% | +$2.38M | 0.01% | 793 |
|
|
2022
Q3 | $2.98M | Buy |
27,200
+3,100
| +13% | +$312K | ﹤0.01% | 1136 |
|
|
2022
Q2 | $1.86M | Buy |
24,100
+10,300
| +75% | +$758K | ﹤0.01% | 1435 |
|
|
2022
Q1 | $1.08M | Sell |
13,800
-11,200
| -45% | -$858K | ﹤0.01% | 2359 |
|
|
2021
Q4 | $2.27M | Sell |
25,000
-4,100
| -14% | -$351K | ﹤0.01% | 1773 |
|
|
2021
Q3 | $2.58M | Buy |
29,100
+7,100
| +32% | +$547K | ﹤0.01% | 1874 |
|
|
2021
Q2 | $1.73M | Sell |
22,000
-22,500
| -51% | -$1.71M | ﹤0.01% | 2138 |
|
|
2021
Q1 | $3.25M | Sell |
44,500
-5,600
| -11% | -$517K | ﹤0.01% | 1462 |
|
|
2020
Q4 | $8.59M | Sell |
50,100
-31,900
| -39% | -$4.73M | 0.01% | 763 |
|
|
2020
Q3 | $11.6M | Buy |
82,000
+40,800
| +99% | +$6.2M | 0.03% | 476 |
|
|
2020
Q2 | $6.7M | Sell |
41,200
-3,700
| -8% | -$504K | 0.02% | 656 |
|
|
2020
Q1 | $4.42M | Sell |
44,900
-82,400
| -65% | -$9.42M | 0.01% | 831 |
|
|
2019
Q4 | $16.4M | Buy |
+127,300
| New | +$12.8M | 0.04% | 450 |
|
|
2019
Q2 | – | Sell |
-221,000
| Closed | -$26.3M | – | 5089 |
|
|
2019
Q1 | $26.3M | Buy |
221,000
+51,500
| +30% | +$6.62M | 0.08% | 194 |
|
|
2018
Q4 | $18.3M | Sell |
169,500
-113,900
| -40% | -$14.2M | 0.05% | 280 |
|
|
2018
Q3 | $45.8M | Buy |
283,400
+123,700
| +77% | +$16.9M | 0.1% | 112 |
|
|
2018
Q2 | $11.8M | Hold |
159,700
| – | – | 0.03% | 428 |
|
|
2018
Q1 | $11.8M | Sell |
159,700
-103,500
| -39% | -$6.9M | 0.03% | 428 |
|
|
2017
Q4 | $14.6M | Sell |
263,200
-149,400
| -36% | -$7.91M | 0.05% | 347 |
|
|
2017
Q3 | $18.7M | Buy |
412,600
+217,300
| +111% | +$8.68M | 0.07% | 235 |
|
|
2017
Q2 | $6.52M | Sell |
195,300
-22,800
| -10% | -$742K | 0.03% | 544 |
|
|
2017
Q1 | $6.33M | Buy |
218,100
+32,200
| +17% | +$997K | 0.03% | 541 |
|
|
2016
Q4 | $5.1M | Sell |
185,900
-46,500
| -20% | -$1.87M | 0.03% | 722 |
|
|
2016
Q3 | $14.2M | Sell |
232,400
-73,400
| -24% | -$2.22M | 0.07% | 333 |
|
|
2016
Q2 | $5.71M | Buy |
+305,800
| New | +$5.66M | 0.03% | 556 |
|
Other funds holding SRPT
EAM
Wolverine Trading's SRPT Position: Q3 2025 in Review
Wolverine Trading increased its Sarepta Therapeutics (SRPT) stake by 20% in Q3 2025, buying an estimated $50.3K and bringing the position to 16,719 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #4310.
Wolverine Trading first reported a position in SRPT in Q3 2016 and has held it in 29 quarters since. The position peaked at $8.79M in Q3 2018. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.
- Wolverine Trading held 16,719 shares of Sarepta Therapeutics worth $315K as of Q3 2025.
- Wolverine Trading bought 2,819 Sarepta Therapeutics shares in Q3 2025, an estimated $50.3K.
- Sarepta Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4310 holding.
- Wolverine Trading first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 29 quarters since.
- Wolverine Trading's Sarepta Therapeutics position peaked at $8.79M in Q3 2018.
- 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.